Article
COMO and CAPRI Trials Evaluate Duravyu in DME
Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses how the COMO and CAPRI phase 3 trials of Duravyu (EyePoint Pharmaceuticals) test a longer-acting approach to diabetic macular edema (DME) treatment.







